Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$33.48M+489.78%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nicholas Stewart Green MBA
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 371
- Beta
- 1.41
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.58
Financials
Revenue
$33.48M+489.8%Net Income
$-17.41MEBITDA
$-10.16MFree Cash Flow
$10.38MEPS (diluted)
$-0.27Shares Outstanding (diluted)
63.84M+144.8%Operating Expenses
$10.59MCash & Debt
$33.41MReturn of Capital
$0.00Revenue by Segment (annual)
$149.27MDividend per Share
$0.66Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2023 | $139.91M | $-140.75M | $-2.23 |
| 2022 | $149.27M | $560.0K | $0.01 |
| 2021 | $119.60M | $127.67M | $2.08 |
| 2020 | $95.87M | $11.21M | $0.06 |
| 2019 | $59.70M | $-7.26M | $-0.13 |
| 2018 | $53.60M | $-4.21M | $-0.08 |
| 2017 | $53.62M | $-21.81M | $-0.46 |
| 2016 | $57.63M | $-28.16M | $-0.76 |
| 2015 | $44.69M | $-55.65M | $-1.80 |
| 2014 | $26.78M | $-50.36M | $-1.93 |
| 2013 | $22.40M | $-35.36M | $-1.53 |
| 2012 | $21.68M | $-29.78M | $-1.73 |
| 2011 | $15.23M | $-42.12M | $-3.53 |
| 2010 | $13.49M | $-34.15M | $-3.93 |
Valuation
CDMOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60+20.00%Social Signal Score
Mentions (8)
- Newsprnewswire.com·17d ago·Positive
Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands October agreement advances the U.S. customer program to approximately $5.1 million in committed base services JERUSALEM, Nov. 5, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today report…
View source ↗ - Newsprnewswire.com·33d ago·Negative
Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing Management estimates operating runway to late 2027, with potential extension into the third quarter of 2028 as later project phases under the recently announced CDMO agreement are activated and delivered JERUSALEM, Oct. 20, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) today issued the following letter to shareholders from Chief Executive Officer Amir Reichman.
View source ↗ - Newsaccessnewswire.com·39d ago·Negative
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge Velocity Bioworks' San Antonio facility offers process development, analytical services, and early-phase clinical drug substance manufacturing for biotechnology companies evaluating U.S.-based production SAN ANTONIO, TX / ACCESS Newswire / October 14, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that ac…
View source ↗ - Newsprnewswire.com·40d ago·Positive
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025 Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports development activity in 2026 and clinical manufacturing planned for 2027 Potential additional clinical manufacturing carries an indicative, uncommitted service-fee value of $5.85 million for late 2027 through…
View source ↗ - Newsnewsfilecorp.com·40d ago·Positive
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercializatio…
View source ↗ - Newsglobenewswire.com·61d ago·Neutral
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead p…
View source ↗ - Newsprnewswire.com·75d ago·Neutral
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALEM, Sept. 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
View source ↗ - Newsprnewswire.com·104d ago·Neutral
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform. JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
View source ↗
Earnings
Typical surprise -108.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Dec 10$-0.27 vs $-0.12miss
- Mon, Sep 9$-0.09 vs $-0.04miss
- Tue, Jul 2$-1.94 vs $-0.04miss
- Wed, Apr 24$-0.08 vs $-0.02miss
- Thu, Dec 7$-0.12 vs $-0.06miss
- Thu, Sep 7$-0.03 vs $-0.03beat
Estimates and results for CDMO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CDMO officers and directors.
- Bought
- —
- Sold
- $78k
0 trades
3 trades
- Richieri Richard A.sold
- Richieri Richard A.sold
- Richieri Richard A.sold
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CDMO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
